biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Advanced Research in Arrhythmogenic Cardiomyopathy

Guest Editor:

Dr. Stephen P. Chelko
Dept. of Biomedical Sciences, College of Medicine, Florida State University, 1115 West Call Street, Tallahassee, FL 32306-4300, USA

Deadline for manuscript submissions:
31 August 2024

Message from the Guest Editor

Arrhythmogenic cardiomyopathy (ACM) is a leading cause of sudden cardiac death (SCD) and a familial, non-ischemic heart disease that can affect both the left and right ventricles. ACM is often considered a “disease of the cardiac desmosome,” as over 60% of cases are associated with pathogenic desmosomal variants. Clinical characteristics involve cardiac dysfunction and increased arrhythmia, whereas pathological traits include myocardial inflammation and fibrofatty replacement of the myocardium. Exercise is a known contributor to disease progression, and patients with ACM are advised against high-intensity exercise or complete exercise cessation. Antiarrhythmics are the mainstay in ACM therapeutics, with treatment strategies directed at preventing fatal ventricular arrhythmias (FVAs) and aborting SCD. The most effective intervention is an implantable cardiac defibrillator, yet this does not prevent pathological disease progression. Recent advancements in therapeutics, albeit often in animal models of ACM, suggest that alternative therapeutics such as gene therapy may prevent these pathological hallmarks and thus avert cardiac dysfunction.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI